Latest news with #pointofcaretesting
Medscape
23-07-2025
- Health
- Medscape
Point-of-Care Testing Cuts Antibiotic Use in Pharyngitis
TOPLINE: Point-of-care testing for group A beta-hemolytic Streptococcus (Strep A) significantly reduced antibiotic prescriptions in children and adults with signs of pharyngitis, even when used as the sole intervention. METHODOLOGY: Researchers performed a meta-analysis of eight randomized controlled trials conducted between 2007 and 2021, evaluating point-of-care testing for Strep A vs standard care. The analysis included 4249 children and adults with pharyngitis, cough, or sore throat who underwent point-of-care testing for Strep A either alone or alongside other interventions. Primary outcomes were the impacts on antibiotic prescriptions, clinical decisions, and patient health outcomes. Secondary endpoints assessed diagnostic accuracy of Strep A testing, including sensitivity and specificity measurements. TAKEAWAY: Point-of-care testing reduced antibiotic prescriptions by 38% compared with standard care (risk ratio [RR], 0.62; P < .0001) and by 41% when it was the sole intervention (RR, 0.59; P < .001). The implementation of point-of-care testing also led to a reduction in inappropriate antibiotic prescriptions (RR, 0.45; 95% CI, 0.31-0.97; P = .038). However, there were no significant differences in the patient health outcomes, such as days until pain resolution and days of school/work missed, the use of ancillary testing, or other medications such as analgesics with point-of-care testing. The reported diagnostic accuracy of Strep A point-of-care testing showed sensitivity ranging from 65% to 94% and specificity from 85% to 94%. IN PRACTICE: 'Physicians can therefore use Strep A POCTs [point-of-care tests] to inform their decisions on antibiotic prescribing without compromising patient health outcomes. In clinical practice, physicians must be aware of the limitations of Strep A POCTs, in particular, the limited sensitivity for detecting GAS [group A beta-hemolytic Streptococcus],' the authors of the study wrote. SOURCE: This study was led by Ann-Sophie Mägdefrau and Carolin Kathner-Schaffert, Jena University Hospital and InfectoGnostics Research Campus Jena, both in Jena, Germany. It was published online on July 9, 2025, in Open Forum Infectious Diseases. LIMITATIONS: High statistical heterogeneity in the meta-analyses limited the precision of the pooled effect estimates. Only three trials reported patient health outcomes, restricting evaluation of the effect of Strep A point-of-care tests on measures like recovery time. Additionally, none of the trials were blinded, introducing potential bias — particularly in evaluating subjective outcomes like pain and symptom resolution. DISCLOSURES: This study received funding from the German Federal Ministry of Education and Research. The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
10-07-2025
- Health
- Yahoo
Japan Point-Of-Care Testing Market Set to Reach US$ 4,557.56 Million By 2033
Japan's point-of-care testing sector is mature, driven by an ageing population, strong domestic champions, supportive reimbursement, and global firms introducing connectivity, yet competitive pressures sustain innovation and ensure secure supply chains across clinics and hospitals. Chicago, July 10, 2025 (GLOBE NEWSWIRE) -- The Japan point-of-care testing market is projected to hit the market valuation of US$ 4,557.56 million by 2033 from US$ 2,361.59 million in 2024 at a CAGR of 7.91% during the forecast period 2025–2033. Japan point-of-care testing market continues to gain strong momentum as the nation's rapidly ageing demographic pushes hospitals, clinics, and community pharmacies to secure nearly instantaneous answers at the bedside. In 2024 the Cabinet Office reports 36 million Japanese residents aged over 65, and this cohort presents the highest per-capita burden of diabetes, heart failure, and chronic respiratory disease nationwide. Traditional central-lab workflows stretch turnaround time to three hours or more, an interval that often triggers avoidable ambulance transfers and overnight admissions. By contrast, handheld HbA1c, BNP, and CRP cartridges now deliver actionable readings within fifteen minutes, enabling physicians to titrate medication in the same visit. Growth is especially visible inside 1,500 geriatric specialty hospitals, where ward nurses increasingly run creatinine or urinalysis strips before nephrologist rounds, preventing dosing errors for renally cleared drugs. Global momentum is supportive; the broader point-of-care diagnostics segment climbed further in 2023, reflecting brisk cartridge replenishment rates across Asia-Pacific. Download Free Sample: Clinical leaders underscore that the Japan point-of-care testing market benefits from strong continuity-of-care objectives under the national 'Community‐based Integrated Care System.' Because nearly one in three ambulance calls involves patients over 75, emergency departments are deploying desktop troponin analyzers at triage to reduce coronary ruling-out time from 170 to 40 minutes. Home-visit nurses, whose numbers surpassed 110,000 in 2024, now carry Bluetooth glucose meters that push encrypted data to family physicians through the MHLW-certified Medical Information Cloud. The keyword impetus is also seen in rehabilitation facilities, where physiotherapists use portable lactate meters to individualize exercise loads. Further demand stems from family caregivers purchasing hemoglobin self-test kits online; e-commerce sales for these kits more than doubled between 2021 and 2023. Altogether, the Japan point-of-care testing market is evolving from hospital-centric instrumentation toward a pervasive, elder-support ecosystem that travels with the patient. Key Findings in Japan Point-Of-Care Testing Market Market Forecast (2033) US$ 4,557.56 million CAGR 7.91% By Product Type Testing Kits & Consumables (65.50%) By Test Type Immunological PoC Tests (45.50%) By Indication Infectious Diseases (35.70%) By Technology Biosensor Technology (30.8%) By Sample Type Blood (62.7%) By Mode of Purchase Prescription-based Testing (53.77%) By End User Hospitals & Clinics (58.5%) By Distribution Channel Retail Pharmacies (46.2%) Top Drivers Aging Population Needs: Rising elderly demographic demands rapid POCT diagnostics in both nations. Chronic Disease Prevalence: Increasing chronic conditions boost POCT demand for early screening. Government Support: Funding from public and private sectors drives POCT market growth. Top Trends Decentralized Testing Growth: Shift to decentralized diagnostics enhances faster decision-making in healthcare. Mobile Device Adoption: Growing use of mobile POCT devices in middle-income regions. Technological Advancements: Innovations in POCT platforms like microfluidics improve testing accuracy. Top Challenges Accuracy Concerns: Inaccurate results reduce trust in POCT versus lab testing. Cost Barriers: High costs limit POCT adoption in resource-constrained settings. Regulatory Hurdles: Stringent regulations in India and Japan complicate market entry. Policy Reforms Accelerate Decentralized Testing Reimbursement And Procurement Pathways Expansion Japan point-of-care testing market immediately felt the impact of the April 2022 revision to the National Health Insurance (NHI) tariff schedule, which created distinct specimen-specific codes for QR-linked lateral-flow assays. Under the update, providers receive a bundled consultation fee when antigen or molecular tests are performed in non-hospital settings, a mechanism that saved clinics an estimated US$ 9.6 million in administrative time during the first twelve months. Likewise, the October 2023 Pharmaceutical and Medical Device Act (PMD Act) amendment simplified importation dossiers for CE-marked cartridge systems, shaving the average approval review period from 14 to 8 months. The Ministry of Economy, Trade and Industry (METI) complemented the regulatory streamlining by launching a four-year, US$ 120 million subsidy program that reimburses up to 50,000 yen per analyte-specific device installed in rural municipalities. Globally, payers that adopt similar outcome-based reimbursement have spurred quicker diagnostics diffusion. Strong fiscal signals guarantee sustained velocity for the Japan point-of-care testing market going into fiscal 2025. The government's 9th Medical Fee Revision allows pharmacists to bill for inflammatory marker testing when undertaken as part of medication therapy management, a first in the OECD community. Prefectural procurement offices are also turning to digital auctions: Tokyo, Kanagawa, and Osaka jointly sourced 280,000 influenza-SARS-CoV-2 combo cassettes via an online reverse-bid in January 2024, securing a 12-day delivery window that supported uninterrupted clinic operations during a severe seasonal surge. Parallel efforts inside the Self-Defense Forces Medical Service have cleared portable blood gas units for disaster drills, providing another reimbursable pathway once units transition to civilian trauma centers. These multilayered fiscal and regulatory levers ensure that the Japan point-of-care testing market is not only expanding its installed base but also lowering the total cost of ownership for frontline providers. Technological Convergence Spurs Multiplex Molecular Panels In Primary Settings Evolution Japan point-of-care testing market registers a clear pivot from single-analyte lateral-flow strips to palm-sized multiplex PCR readers capable of detecting ten respiratory or gastrointestinal pathogens in one cartridge. Domestic innovators, often in partnership with microfluidic design houses from Silicon Valley, have shrunk thermal-cycling volumes to under two microliters, trimming reaction times to 20 minutes without sacrificing analytical sensitivity. The 2024 Kanto Respiratory Trial demonstrated that a clinic-based multiplex panel correctly identified 219 out of 222 adenovirus cases compared with central-lab RT-PCR, while allowing same-visit antiviral prescription. On the chronic-disease front, electrochemical immunosensors embedded in chip-on-board assemblies now quantify hs-CRP down to 0.2 mg/L, enabling earlier statin initiation for patients who appear low-risk by LDL alone. These advances mirror the global move toward high-throughput, cartridge-based POCT solutions that continue to attract strategic investment. Interoperability standards are equally decisive in directing capital toward the Japan point-of-care testing market. Every major cartridge platform released since mid-2023 ships with FHIR-compatible middleware, meaning encounter data slip seamlessly into the nationwide KokusaiDenso distributed ledger used for claims adjudication. That single feature shortened claim reconciliation cycles by four days for 380 pilot clinics across Saitama Prefecture. Additionally, the Japan Electronics and Information Technology Industries Association (JEITA) published a common battery-safety profile that lets clinicians hot-swap lithium-ion packs without rebooting the analyzer—a critical requirement for disaster preparedness hospitals in quake-prone regions. The confluence of microfluidics, cloud APIs, and ruggedized industrial design places the Japan market on a trajectory where precision diagnostics are not compromised by footprint, power, or data-security constraints. Modify Report as Per Requirements: Domestic Champions Compete With Multinationals In Connected Device Arena Dynamics Japan point-of-care testing market features a vibrant mix of home-grown players—Sysmex, ARKRAY, HORIBA, and Nihon Kohden—alongside multinational heavyweights Abbott, Roche, and Siemens Healthineers. Local manufacturers leverage intimate knowledge of reimbursement nuance and facility layout; Sysmex's XW-1000 hematology analyzer, purpose-scaled to fit on Japan's standard 600-millimeter dispensing counter, reached 4,200 community clinics within its first 18 months of launch. Multinationals counter with global R&D budgets, introducing connectivity features such as Abbott's ID NOW Japanese-language voice guidance that reduces operator training time by 60 minutes per staff member. Market watchers observe that platform loyalty increasingly hinges on cartridge supply resilience—domestic suppliers maintained 98 percent monthly fill rates during the Q1 2024 influenza surge, whereas two overseas brands reported week-long back orders. Competitive intensity keeps pricing disciplined, but the bigger story is ecosystem control within the Japan point-of-care testing market. Sysmex secured an exclusive middleware contract with the National Cancer Center Hospital East, linking 65 desk-top coag meters and 22 urinalysis imagers across five buildings; the network transmits 1.2 million results annually into a single data lake for AI-driven antimicrobial stewardship. The system's first-year pilot cut average empirical-antibiotic days of therapy (DOT) by 14 % and flagged 230 mismatches between antibiograms and prescription patterns—metrics that Sysmex now packages into a subscription analytics module to be rolled out to 40 prefectural cancer centers by 2026. Rivals have responded quickly: Roche coaxed its cobas® h 232 cardiac POC line onto NHO's national VPN, while Nihon Kohden embedded FHIR-ready hooks in the new Life Scope PT vitals monitor so that sepsis alerts flow directly into Cerner and Fujitsu HIS instances without middleware. Japan Point-of-Care Testing Market Major Players: Abbott Laboratories F. Hoffmann-La Roche Ltd Sekisui Diagnostics BD (Becton, Dickinson and Company) FUJIFILM Sysmex Corporation Other Prominent Players Key Market Segmentation: By Product Devices & Instruments Diagnostic Analyzers & Testing Devices Blood Gas & Electrolyte Analyzers Cardiac Biomarker Analyzers Glucose Monitoring Devices Coagulation Testing Analyzers Urinalysis Analyzers Routine Clinical Chemistry Analyzers Others Monitoring Devices Blood Pressure Monitors Thermometers Pulse Oximeters Others Testing Kits & Consumables Blood Gas & Electrolyte Test Kits Cardiac Biomarker Test Kits Routine Clinical Chemistry Test Kits Hematology Test Kits Coagulation Testing Kits Urinalysis Test Strips & Kits Cholesterol Test Strips Drugs Abuse Testing Kits Pregnancy And Fertility Testing Kits Others By Test Type Immunological PoC Tests Nucleic Acid-Based PoC Tests Biomarker-Based PoC Tests By Indication Infectious Diseases HIV COVID-19 Others Oncology Cardiovascular Diseases Metabolic Disorders Respiratory Diseases Neurological Disorders Gastrointestinal Disorders Others By Technology Biosensor Technology Microfluidic Lab-On-A-Chip Technology Molecular Diagnostics Immunoassays Others By Sample Type Blood Urine Saliva Others By Mode Of Purchase Prescription-based Testing Over the Counter (OTC) Testing By End User Hospitals & Clinics Diagnostic Centers Homecare Settings Research Laboratories Others By Distribution Channel Direct Distribution Retail Pharmacies Online Pharmacies Others Have Questions? Reach Out Before Buying: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Growing Demand for Point-of-Care (POC) Testing and Expanding Applications Beyond Healthcare
The U.S. and Europe lateral flow assay market is expected to reach USD 6.97 billion by 2030, with a 5.48% CAGR from 2025. Growth is driven by the rise in point-of-care testing, advancements in testing technologies, and increased demand during and beyond COVID-19. Emerging trends include digital integration and enhanced assay sensitivity. The report offers insights into major market segments, end-user analysis, and future trends, empowering strategic business decisions. U.S. And European Lateral Flow Assay Market Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "U.S. And Europe Lateral Flow Assay Market Size, Share & Trends Analysis Report Product (Kits & Reagents, Lateral Flow Readers), By Application, By Technique, By Test Type, By End Use, By Country, And Segment Forecasts, 2025 - 2030" report has been added to U.S. and Europe lateral flow assay market size is anticipated to reach USD 6.97 billion by 2030 and is projected to grow at a CAGR of 5.48% from 2025 to 2030 This growth is driven by the increasing decentralization of diagnostic services, rapid adoption of point-of-care testing (POCT), advancements in rapid testing technologies, and the positive shift toward self-testing strategies. In addition, the rising prevalence of infectious diseases and heightened awareness of rapid test kits during the COVID-19 pandemic have created favorable conditions for the lateral flow assay market's expansion. The integration of digital technologies into lateral flow devices is another pivotal trend. Smartphone-based readers, as well as highly customized stand-alone LFA readers, have allowed users to obtain semi-quantitative or fully quantitative results from traditionally qualitative assays. These technologies not only have the potential to improve diagnostic accuracy but also enable real-time data sharing for epidemiological tracking and disease management. The increasing prevalence of infectious diseases throughout the world is a key driver fueling the expansion of the lateral flow assay market. These diseases necessitate novel diagnostic techniques for efficient treatment to stop the rising mortality high prevalence of infectious diseases worldwide has been a major driver for the market growth. These diseases necessitate novel diagnostic techniques for efficient treatment to stop the rising mortality rate. The COVID-19 pandemic, in particular, highlighted the need for rapid and accessible diagnostic tools, leading to a surge in demand for LFAs. Beyond COVID-19, other infectious threats have emerged. For instance, in 2025, a highly pathogenic avian influenza A (H5N1) virus infection resulted in a fatality in Louisiana, USA, despite the use of personal protective equipment that was deemed inadequate. According to the Centers for Disease Control and Prevention (CDC), while the general public faces a low risk, individuals working closely with infected animals-such as farmers, veterinarians, and wildlife facility staff-remain highly vulnerable. In 2024, 67 human cases of avian influenza were reported, with 40 linked to exposure to dairy cattle and 23 associated with poultry farms. In response, the UK proactively secured 5 million doses of the H5 vaccine to mitigate potential risks in in LFA technology have significantly improved the sensitivity, specificity, and overall performance of these assays, thereby expanding their applications. In December 2021, Eurofins Technologies introduced the RapidScan ST5-W lateral flow reader, designed for field and in-process testing applications that require qualitative to semi-quantitative test results. Traditionally, commercial LFA test strips utilize the red coloration of gold nanoparticles (GNPs) or colored beads for detection. LFAs have proven highly sensitive in diagnosing diseases like HIV-AIDS, Hepatitis B, and C and assessing immune responses against signal amplification techniques, including silver enhancement and GNP-enzyme conjugation (such as horseradish peroxidase), have significantly improved detection capabilities. Furthermore, integrating electrochemical sensing, Surface-Enhanced Raman Spectroscopy (SERS), fluorescence detection, and nanoparticles have enhanced the specificity of LFAs, allowing for multiplex detection and faster diagnostics. Future advancements, including next-generation chips, DNA amplification, and CRISPR-based technologies, hold the potential to improve LFA performance further. The use of quantum and nanomaterials is also being explored to boost convenience and accessibility of home-based testing have led to increased adoption of LFAs among consumers. In September 2024, InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, obtained 510(k) clearance from the USFDA for its SCoV-2 Ag Detect Rapid Test. Featuring a patent-pending design, this user-friendly rapid antigen test requires no additional equipment or mixing, can be stored at room temperature, and delivers results in just 20 minutes-offering a simple and accessible COVID-19 testing solution for home use. Beyond COVID-19, InBios International Inc. has secured a USD 16.5 million project aimed at enhancing the design of its Active Melioidosis Detect Plus (AMD Plus) device. The funding will support performance validation and regulatory approvals, demonstrating the growing investment in LFA-based diagnostics for infectious diseases beyond the pandemic. In December 2024, the USFDA approved the OraQuick HIV Self-Test, a qualitative immunoassay designed to detect antibodies to HIV-1 and HIV-2 in oral fluid samples. Intended for over-the-counter (OTC) use, this test offers individuals a discreet and reliable way to screen for HIV at home, contributing to early diagnosis and timely medical intervention.U.S. And Europe Lateral Flow Assay Market Report Highlights The kits & reagents segment led the market with the largest revenue share of 68.48% in 2024, driven by technological advancements and rising demand for rapid diagnostics. Innovations in assay sensitivity, specificity, and ease of use have significantly contributed to market expansion. Based on application, the clinical testing segment led the market with the largest revenue share of 77.18% in 2024. This growth is fueled by the increasing prevalence of infectious diseases and chronic conditions, along with the rising demand for rapid diagnostic solutions. Based on technique, the sandwich assay segment led the market with the largest revenue share of 39.66% in 2024, driven by its accuracy, affordability, and ease of use. These assays are particularly valuable in low-resource healthcare settings, as they do not require trained personnel. Sandwich assays are commonly used to detect larger analytes that contain two epitopes or binding sites. Based on test type, the lateral flow immunoassay (LFIA) segment led the market with the largest revenue share of 65.10% in 2024, solidifying its position as a widely used platform for rapid diagnostics since its introduction in the mid-1980s. Due to their ease of use, cost efficiency, and quick results, LFIA tests are highly adaptable, allowing for administration by healthcare professionals and patients at home. Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 35.99% in 2024. As primary diagnostic and treatment centers, hospitals and clinics play a crucial role in driving LFA adoption across the U.S. and Europe. The U.S. market is experiencing robust growth, driven by continuous product innovation, strategic investments, and strong government support. Advances in LFA technology have significantly enhanced sensitivity and broadened applications, fueling market expansion. Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.19 Billion Forecasted Market Value (USD) by 2030 $6.97 Billion Compound Annual Growth Rate 5.4% Regions Covered Europe, United States Market Dynamics Market Drivers Analysis Increasing prevalence of infectious diseases Technological advancements in lateral flow Growing adoption in homecare settings Market Restraints Analysis Stringent Regulations Market Opportunities Analysis Growing demand for Point-of-Care (POC) Testing Expanding applications beyond healthcare Market Challenges Analysis Product Recalls U.S. and Europe Lateral Flow Assay Market Analysis Tools Porter's Analysis Bargaining power of the suppliers Bargaining power of the buyers Threats of substitution Threats from new entrants Competitive rivalry PESTEL Analysis Political landscape Economic and Social landscape Technological landscape Environmental landscape Legal landscape Companies Featured Abbott Bio-Rad Laboratories, Inc Siemens Healthineers AG BIOMERIEUX BD QIAGEN QuidelOrtho Corporation F. Hoffmann-La Roche DH Life Sciences, LLC. Quest Diagnostics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. And European Lateral Flow Assay Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
